Business Wire

ME-COVETRUS

Share
Covetrus Integrates Telemedicine Capabilities Across Its Global Technology Portfolio

Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, announced today that it is embedding secure video teleconferencing capabilities across the company’s global suite of practice information management systems (PIMS), client communications, and prescription management solutions. This new functionality provides a seamless and easily accessible way for veterinarians to service their clients and patients remotely using their existing Covetrus technology solutions.

“It is inspiring to see the veterinary community in action as they work even harder to support and provide care to their clients during the COVID-19 pandemic. To further help, we directed our efforts into fast-tracking a product extension for telemedicine that we expect to be even more impactful in the current environment,” said Georgia Wraight, president, Covetrus Global Technology Solutions. “By making this functionality available across our suite of technology solutions, those that our customers already know and use daily in their practice, we hope to ease and enhance the ways in which veterinarians are able to maintain care with their clients throughout this crisis … and after.”

To support the veterinary community during the COVID-19 pandemic, all users of Covetrus technology platforms will have free access to video conferencing capabilities, until further notice. Starting today, users of the Rapport™ client communications product have access to video conferencing, further building on its two-way, omni-channel messaging via email, text, and now video. In the coming weeks, Covetrus will also launch these secure video capabilities directly into its PIMS, including AVImark® , eVetPractice® and ImproMed® , as well as its prescription management platform. International platforms, including RxWorks in Australia and RoboVet in the U.K., will also gain this advanced functionality.

“The Rapport client communication system is already a critical tool for us to stay in touch with our clients about their appointments and care,” said Alinda Higgins, CVT, manager, East Lake Hospital for Animals, Ltd. “With video conferencing, we’ll not only be able to maintain communication, but make it easier for us to actively deliver care for our patients. It's the next best thing to having the patient physically in front of you. During times when everything seems more complex, Covetrus has come through to make patient care safe and more convenient for our clients and their pets.”

Covetrus will offer user training for this new capability along with their series of educational webinars aimed at navigating the COVID-19 pandemic. For more information about the new video capability now available in Rapport, and to keep updated on the timing of upcoming releases into the Covetrus suite of technology, go to https://get.covetrus.com/rapport-telemedicine .

This week’s webinar features VMX Speaker of the Year, Eric Garcia in a session titled “Navigating Client Communications Amid COVID-19”. In this one-hour webinar, Garcia will discuss how to maintain and build connections with clients during this challenging time. The webinar will take place Thursday, April 16th at 12:00 p.m. EDT. To register go to: rxmanagement.covetrus.com/webinars .

About Covetrus
Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We’re bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine, with more than 5,500 employees, serving over 100,000 customers around the globe. Learn more at covetrus.com .

Forward-Looking Statements 
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our plans, objectives, expectations, and intentions. Such statements are subject to numerous risks and uncertainties. Factors that could adversely affect our business and prospects are set forth in our public filings with the Securities and Exchange Commission. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release

Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through

Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release

Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release

Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These

2026 Mitsui Chemicals Catalysis Science Awards18.11.2025 03:00:00 CET | Press release

Online applications are open until December 25, 2025 Mitsui Chemicals, Inc. has announced that online applications for the 2026 Mitsui Chemicals Catalysis Science Award have been open since September 1, 2025. The application period will run from September 1 to December 25, 2025. Aiming to contribute to the sustainable development of chemistry and the chemical industry, Mitsui Chemicals established the Mitsui Chemicals Catalysis Science Awards in 2004. The awards consist of the Catalysis Science Award and the Catalysis Science Award for Creative Work, which recognize outstanding achievements in the field of catalysis science. To date, the awards have been conferred on 33 researchers within Japan and overseas. Past recipients include individuals who have gone on to be highly acclaimed worldwide, receiving honors such as the Nobel Prize in Chemistry and other prestigious Japanese and international awards. We welcome applications from a wide range of R&D fields, including solid catalysts,

Access Advance Welcomes Xiaomi to HEVC Advance and VVC Advance Patent Pools as a Licensor and Licensee18.11.2025 02:00:00 CET | Press release

Access Advance LLC, an independent licensing administrator for leading video codec patent pools, today announced that Xiaomi has joined the HEVC Advance Patent Pool and the VVC Advance Patent Pool, as a Licensor and Licensee. "We are delighted to welcome Xiaomi to the Access Advance licensing community," said Peter Moller, CEO of Access Advance. "Xiaomi's participation in both our HEVC and VVC patent pools represents a significant milestone in the video codec licensing landscape. Their joining of the HEVC Advance Patent Pool, which provides them with access to tens of thousands of essential patents for the widely adopted H.265 standard, and their dual role as both a licensor and licensee in the VVC Advance Patent Pool, demonstrates their commitment to innovation and the recognition of the value of patent pools that balance the interest of patent owners and implementers. In addition, it highlights their support for Access Advance’s efforts to bring a one-pool solution to video codec lic

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye